Evidence map›Paper›PMID 41385624›Full record

ArticleScience advances2025

Chiral sodium complex-catalyzed asymmetric cascade cycloaddition/hydration/1,2-rearrangement.

Ming Zhang, Yuanlin Wei, Man Zhao, Shiyu Xu, Ying Wang, Yuhong Yang, Guofeng Li, Rui Wang, Liang Hong

Abstract read
In one paragraph

Article in Science advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ming ZhangGuangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.ORCID 0000-0002-8879-1956
Yuanlin WeiGuangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.ORCID 0009-0001-2009-541X
Man ZhaoSchool of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen 518055, China.
Shiyu XuGuangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.
Ying WangSchool of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen 518055, China.
Yuhong YangSchool of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen 518055, China.
Guofeng LiSchool of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen 518055, China.ORCID 0000-0002-7528-2036
Rui WangSchool of Pharmacy, Shenzhen University Medical School, Shenzhen University, Shenzhen 518055, China.ORCID 0000-0002-4719-9921
Liang HongGuangdong Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou 510006, China.ORCID 0000-0002-3489-0633

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The research on the coordination chemistry and catalytic applications of sodium ions is of great importance. Inspired by the sodium ions-activated enzymes, we explored a sodium complex based on the synergistic coordination of polyfluorophosphate anions and water molecules. X-ray crystallography and computational chemistry revealed its unique spatial structure and highlighted the activation state of the water molecules within the chiral cavity. Furthermore, we have successfully applied the sodium complex in the catalysis of α-ketoimine-type 1,2-rearrangement, overcoming challenges of background reaction and competitive inhibition, ultimately achieving the construction of a series of chiral N-fused polycyclic isoquinolines with remarkable enantioselectivity. Mechanism studies shown that sodium complex activate and regulate water molecules to achieve highly stereoselective hydration process in the chiral environment and generate the key chiral 1,2-diol intermediate. Our research brings insights into the design and application of group 1 metal complexes and provides an approach to the development of asymmetric 1,2-rearrangement reactions.

Identifiers

PMID41385624
PMCPMC12700193

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.